Robert S. Epstein, M.D., has served on Veracyte’s board of directors since 2015, including as Chairman since 2023.
From 2010 to 2012, Dr. Epstein served as President of the Medco-UBC Division and as Chief Research and Development Officer of Medco Health Solutions, Inc., a managed healthcare company.
Prior to that, Dr. Epstein served as Medco’s Chief Medical Officer from 1997 to 2010.
He is a member of the board of directors of Fate Therapeutics, Inc. and Illumina, Inc. and previously served as a member of the board of directors of Aveo Pharmaceuticals, Inc. and of Decipher Biosciences, where he was Chairman.
Dr. Epstein is the former President of the International Society of Pharmacoeconomics and Outcomes Research, and served on the board of directors of the Drug Information Association and the International Society of Quality of Life.
He has also served on the Centers for Disease Control and Prevention’s Evaluation of Genomic Applications in Practice & Prevention Stakeholder Committee and the Agency for Healthcare Research and Quality Centers for Education and Research on Therapeutics Committee.
Dr. Epstein holds a B.S. in Biomedical Science and an M.D. from the University of Michigan and an M.S. in Preventive Medicine from the University of Maryland.
What is Robert S. Epstein's net worth?
The estimated net worth of Robert S. Epstein is at least $2.48 million as of May 20th, 2026. Epstein owns 52,446 shares of Veracyte stock worth more than $2,479,857 as of June 2nd. This net worth estimate does not reflect any other assets that Epstein may own. Learn More about Robert S. Epstein's net worth.
How do I contact Robert S. Epstein?
Has Robert S. Epstein been buying or selling shares of Veracyte?
Over the course of the past ninety days, Robert S. Epstein has sold $440,100.00 of Veracyte stock. Most recently, Robert S. Epstein sold 10,000 shares of the business's stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $44.01, for a transaction totalling $440,100.00. Following the completion of the sale, the director now directly owns 52,446 shares of the company's stock, valued at $2,308,148.46. Learn More on Robert S. Epstein's trading history.
Who are Veracyte's active insiders?
Veracyte's insider roster includes Bonnie Anderson (Insider), Muna Bhanji (Director), Rebecca Chambers (Exec. VP & CFO ), Rebecca Chambers (CFO), Karin Eastham (Director), Robert Epstein (Director), Phillip Febbo (Insider), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), Annie Mcguire (SVP), Marc Stapley (CEO), Marc Stapley (CEO & Director), Jonathan Wygant (CAO), and Jonathan Wygant (CAO). Learn More on Veracyte's active insiders.
Are insiders buying or selling shares of Veracyte?
In the last year, insiders at the biotechnology company sold shares 23 times. They sold a total of 272,920 shares worth more than $11,242,716.98. The most recent insider tranaction occured on May, 22nd when CAO Jonathan Wygant sold 24,000 shares worth more than $1,089,600.00. Insiders at Veracyte own 1.4% of the company.
Learn More about insider trades at Veracyte. Information on this page was last updated on 5/22/2026.
